Immunhistochemische Untersuchungen zum Proliferationsverhalten und Hormonrezeptorstatus bei Mammakarzinomen unter besonderer Berücksichtigung der HER-2/neu-Expression

Zusammenfassung

Das Mammakarzinom ist der häufigste gynäkologische Tumor. Das HER-2/neu-Onkogen könnte für die Prognose und die Therapieplanung von Mammakarzinompatienten eine Rolle spielen. In einer retrospektiven Studie haben wir an 100 Patienten die Expression dieses Onkogens mit den klassischen klinischen und pathologischen Faktoren korreliert. 32 % der untersuchten Patienten zeigten eine HER-2/neu-Überexpression. Es zeigte sich aber kein signifikanter Zusammenhang zu den bisherigen Parametern. Dies könnte bedeuten, dass mit der Bestimmung des HER-2/neu-Onkogens ein neuer unabhängiger Prognosefaktor gefunden ist. Prospektive Studien, die einen Zusammenhang zwischen der HER-2/neu-Überexpression und der Prognose herstellen, könnten zusätzlich Informationen liefern.

Abstract

Breast cancer is the most frequent gynecological tumor. The HER-2/neu onkogene may play a role in the prognosis and management of patients with breast cancer. In a retrospective study on 100 patients, we correlated the expression of this onkogene with the classic clinical and pathological factors. 32 % of patients exhibited overexpression of HER-2/neu. There was no significant correlation with classic parameters. This finding could indicate that HER-2/neu expression is a new independent prognostic factor. Prospective studies correlating HER-2/neu overexpression with prognosis might provide additional data.

Mammakarzinom - HER-2/neu-Überexpression

Breast cancer - HER-2/neu-overexpressing

• 1 An H X, Niederacher D, Beckmann M W, Gohring U J, Scharl A, Picard F. et al . ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues.  Int J Cancer. 1995;  64 (5) 291-297
• 2 Barnes D M, Lammie G A, Millis R R, Gullick W L, Allen D S, Altman D G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.  Br J Cancer. 1988;  58 (4) 448-452
• 3 Baselga J, Norton L, Albanell J, Kim Y M, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.  Cancer Res. 1998;  58 (13) 2825-2831
• 4 Beckmann M W, Niederacher D, Massenkeil G, Tutschek B, Beckmann A, Schenko G. et al . Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients.  Oncology. 1996;  53 (6) 441-447
• 5 Beckmann M W, Niederacher D, Schnurch H G, Bender H G. The erbB gene family: significance for tumor development, prognosis and new therapeutic modalities.  Geburtshilfe Frauenheilkd. 1993;  53 (11) 742-753
• 6 Bishop J M. The molecular genetics of cancer.  Science. 1987;  235 (4786) 305-311
• 7 Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation.  Oncogene. 1991;  6 (1) 137-143
• 8 Borg A, Tandon A K, Sigurdsson H, Clark G M, Ferno M, Fuqua S A. et al . HER-2/neu amplification predicts poor survival in node-positive breast cancer.  Cancer Res. 1990;  50 (14) 4332-4337
• 9 Carter P, Presta L, Gorman C M, Ridgway J B, Henner D, Wong W L. et al . Humanization of an anti-p185HER2 antibody for human cancer therapy.  Proc Natl Acad Sci USA. 1992;  89 (10) 4285-4289
• 10 Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, Di Leo A. et al . Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.  Am J Clin Pathol. 2000;  113 (5) 675-682
• 11 Gilewski T, Seidman A, Norton L, Hudis C. An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.  Cancer Chemother Pharmacol. 2000;  46 (Suppl) S23-26
• 12 Göhring U J, Aslan-Schadwinkel Y, Scharl A. Expression of the p185neu oncoprotein indicates an unfavorable prognosis in small, node negative breast cancer without systemic adjuvant treatment (T1N0).  Geburtshilfe Frauenheilkd. 1993;  53 (9) 625-629
• 13 Gullick W J, Love S B, Wright C, Barnes D M, Gusterson B, Harris A L. et al . c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.  Br J Cancer. 1991;  63 (3) 434-438
• 14 King C R, Kraus M H, Aaronson S A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma.  Science. 1985;  229 (4717) 974-976
• 15 Lewis G D, Figari I, Fendly B, Wong W L, Carter P, Gorman C. et al . Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.  Cancer Immunol Immunother. 1993;  37 (4) 255-263
• 16 McCann A H, Dervan P A, O'Regan M, Codd M B, Gullick W J, Tobin B M. et al . Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.  Cancer Res. 1991;  51 (12) 3296-3303
• 17 Mitze M, Beck T, Weikel W, Rosenthal H, Knapstein P G. Significance of neu-protein for prognosis of breast cancers.  Geburtshilfe Frauenheilkd. 1990;  50 (10) 771-776
• 18 Nicholson R I, McClelland R A, Finlay P, Eaton C L, Gullick W J, Dixon A R. et al . Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.  Eur J Cancer. 1993;  7 (23) 1018-1023
• 19 O'Reilly S M, Barnes D M, Camplejohn R S, Bartkova J, Gregory W M, Richards M A. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.  Br J Cancer. 1991;  63 (3) 444-446
• 20 Paik S, Hazan R, Fisher E R, Sass R E, Fisher B, Redmond C. et al . Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.  J Clin Oncol. 1990;  8 (1) 103-112
• 21 Ridolfi R L, Jamehdor M R, Arber J M. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.  Mod Pathol. 2000;  13 (8) 866-873
• 22 Ross J S, Fletcher J A. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.  Oncologist. 1998;  3 (4) 237-252
• 23 Sahin A A. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer.  Adv Anat Pathol. 2000;  7 (3) 158-166
• 24 Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.  Science. 1987;  235 (4785) 177-182
• 25 Slamon D J, Godolphin W, Jones L A, Holt J A, Wong S G, Keith D E. et al . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.  Science. 1989;  244 (4905) 707-712
• 26 Steffen S M. Immunhistochemische Untersuchungen zum Proliferationsverhalten und Hormonrezeptorstatus bei Mammakarzinomen unter besonderer Berücksichtigung der HER-2/neu-Expression. Greifswald: Ernst-Moritz-Arndt Universität 2001
• 27 Tandon A K, Clark G M, Chamness G C, Ullrich A, McGuire W L. HER-2/neu oncogene protein and prognosis in breast cancer.  J Clin Oncol. 1989;  7 (8) 1120-1128
• 28 Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H. et al . Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int- 2 and c-erbB-2/ear-1.  Cancer Res. 1989;  49 (11) 3104-3108
• 29 Wright C, Angus B, Nicholson S, Sainsbury J R, Cairns J, Gullick W J. et al . Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.  Cancer Res. 1989;  49 (8) 2087-2090
• 30 Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N. et al . Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.  Nature. 1986;  319 (6050) 230-234